Erythropoietin to Improve Critical Care Patient Outcomes

University Hospital, Angers42 enrolled

Overview

Recently, the french societies for critical care (SFAR and SRLF) produced guidelines for anemia treatment in critically ill patients that recommend the use of erythropoietin (EPO) in these patients, but the european society (ESICM) recommended against the use of EPO in this patients, despite recent meta analysis showing a lower mortality in patients treated with EPO. Nevertheless, RCT on EPO in the ICU are quite all, new data are thus needed. Before conducting a large study on EPO in anemic patients in the ICU, we propose to cinduct a feasability RCT to evaluate the feasability of such a study.

Anemia is very common in intensive care patients, affecting approximately two-thirds of patients on admission, with a mean admission hemoglobin (Hb) level of 11.0 g/dl. The severity of anemia is associated with increased morbidity and mortality. Its pathophysiology is complex, involving blood loss (from repeated blood sampling, invasive procedures, surgical interventions, etc.) and inflammation. The latter is responsible for a decrease in endogenous erythropoietin (EPO) production and a decreased bone marrow response, which can be very prolonged (half of the patients discharged from ICU with anemia are still anemic at 6 months of discharge, with low levels of EPO, compared to the observed Hb levels). On this basis, several randomized clinical trials (RCTs) evaluating the effect of EPO on the transfusion rate in this population were performed in the 1990s-2000s. The authors showed a modest reduction in blood transfusion, which was not considered clinically relevant in view of the cost of EPO at that time. Since then, meta-analyses evaluating the benefits and risks of EPO in intensive care patients suggest a positive impact of EPO on mortality. The largest, including 34 studies (and 930,470 patients) reports a reduction in the relative risk of mortality of 0.76, 95% CI \[0.61 - 0.92\]. Beyond the reduction in red blood cell transfusions, the benefit of EPO could be directly due to its erythropoietic effect (correction of anemia) and/or its anti-inflammatory/anti-apoptotic properties. Based on this literature, the French critical care societies have recently recommended the use of EPO. However, the European Society of Intensive Care Medicine (ESICM) recently recommended against the use of EPO, based on the same literature, but suggested that the benefit of EPO should be evaluated. Indeed, the main obstacle to recommending the use of EPO seems to be economic, whereas the arrival on the market of biosimilar molecules has significantly reduced these costs. Most of the trials on EPO in critical care patients (and included in the meta-analyses) are quite old (about 15 years) and none of them had mortality as primary endpoint. In addition, transfusion practices and the quality of blood products have changed significantly over the years. In this context of disagreement on the recommendations for the use of EPO in these patients, but of potential benefit on mortality, there is an urgent need to evaluate whether EPO decreases mortality in adult anemic patients admitted to intensive care. However, calculation of the number of patients needed to evaluate the benefit of EPO on mortality in this population yields a number of patients to be included of the order of 1800-2000 patients. Before considering the implementation of a multicenter study involving such a large number of patients, a pilot study evaluating the feasibility and inclusion capacity for such a study seems indispensable according to the latest CONSORT recommendations.

Conditions

Anemia Intensive Care

Interventions

ErythropoietinDRUG

Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized). The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations. Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.

PlaceboDRUG

In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule. The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations. Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (age \> 18 years), * admitted to intensive care for more than 72 hours and less than 7 days * who have received invasive ventilatory support and/or treatment with a vasoactive agent for at least one day since admission * with an Hb level \< 12 g/dl, * with consent from the patient or patient's relative (or emergency inclusion procedure). Exclusion Criteria: * Moribund patient, * Current hospitalization for acute coronary syndrome, * Recent history of thromboembolic event (\< 3 months), * Uncontrolled hypertension despite adequate antihypertensive therapy, * Myelodysplasia or chronic pathology requiring iterative transfusions, * EPO treatment within the last 30 days, * Participation in another interventional trial of an erythropoiesis-stimulating agent or anemia treatment, * Expected discharge from the intensive care unit within 24 hours, * Known hypersensitivity to EPO or any of its components, * A history of erythroblastopenia following erythropoietin therapy * Pregnant, breast-feeding or parturient woman * Person deprived of liberty by judicial or administrative decision * Person under forced psychiatric care * Person under a legal protection measure.

Locations (2)

Cholet Hospital

Cholet, France

UH Tours

Tours, France

Outcomes

Primary Outcomes

Recruitment rate

≥50% of eligible patients will need to be enrolled, but the trial will not be feasible if the inclusion rate is ≤ 25% or less

Time frame: 90 days

Adherence to allocation groups

A high level of matching of randomization and group allocation should be achieved, with at least 85% of included patients receiving protocol-allocated treatment, but if ≤ 65% patients receive protocol-allocated treatment, the trial is not feasible

Time frame: 90 days

Completion of follow-up of included patients

≥ 85% of patients should be followed through to the end of follow-up, but if \<65% patients are followed through to the last visit, the protocol will not be feasible

Time frame: 90 days

Secondary Outcomes

The proportion of patients lost to follow-up at each visit

Time frame: 7, 14, 21, 28 and 90 days

The rate of missing data for mortality outcome

Time frame: 90 days

The rate of compliance with the therapeutic protocol at each visit for inpatients

Time frame: 7, 14, 21, and 28 days

Mean serum hemoglobin value

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.